What is the NOPR?
The National Oncologic PET Registry (NOPR) was developed in response to the Centers for Medicare and Medicaid Services (CMS) proposal to expand coverage for positron emission tomography with F-18 fluorodeoxyglucose (PET) to include cancers and indications not presently eligible for Medicare reimbursement. Medicare reimbursement for these cancers can now be obtained if the patient’s referring physician and the provider submit data to a clinical registry to assess the impact of FDG-PET on cancer patient management. The NOPR is implementing this registry for CMS. The NOPR is sponsored by the Academy of Molecular Imaging (AMI) and managed by the American College of Radiology (ACR) through the American College of Radiology Imaging Network (ACRIN).
The National Oncologic PET Registry (NOPR) was developed in response to the Centers for Medicare and Medicaid Services (CMS) proposal to expand coverage for positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) to include cancers and indications not presently eligible for Medicare reimbursement. Medicare reimbursement for these cancers can be obtained if the patients referring physician and the provider submit data to a clinical registry to assess the impact of FDG-PET on cancer patient management. The NOPR has implemented this registry for CMS. The NOPR is sponsored by the Academy of Molecular Imaging (AMI) and managed by the American College of Radiology (ACR) through the American College of Radiology Imaging Network (ACRIN).
The National Oncologic PET Registry (NOPR) was developed in response to the Centers for Medicare & Medicaid Services (CMS) proposal to expand coverage for positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) to include cancers and indications not presently eligible for Medicare reimbursement. Medicare reimbursement for these PET studies can be obtained if the patient’s referring physician and the provider submit data to a clinical registry to assess the impact of FDG-PET on cancer patient management. The NOPR has implemented this registry for CMS. In addition, in 2011, the NOPR implemented another component of the registry to assess the impact of PET with sodium fluoride F-18 (NaF-PET) used to identify bone metastasis on cancer patient management. The NOPR is sponsored by the Academy of Molecular Imaging (AMI) and managed by the American College of Radiology (ACR) through the American College of Radiology Imaging Network (ACRIN).
Related Questions
- Can the NOPR be Used for NaF-PET Studies Performed for Indications Other Than Evaluation of Bone Metastases?
- Are Medicare Advantage Beneficiaries Who Participate in the NOPR Liable for Deductible or Co-Payment?
- Can the NOPR be Used for PET Studies Performed with Radiopharmaceuticals Other Than FDG or NaF ?
